Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,633

Document Document Title
WO/2022/167057A1
The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention a...  
WO/2022/167471A1
The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention a...  
WO/2022/169948A1
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...  
WO/2022/169218A1
The present specification pertains to: a method for preparing a deuterated anthracene compound, the method comprising a step of reacting a halogenated benzene having at least one deuterium with enolate to synthesize a deuterated anthrace...  
WO/2022/160390A1
Disclosed are a method for preparing deuterium gas and a deuteration reaction using same as a deuterium source. The method for preparing deuterium gas comprises the following steps: dissolving aluminum into liquid metal gallium to obtain...  
WO/2022/161897A1
The present invention relates to a method for purifying radiolabelled human serum albumin macroaggregates (MAA) in a solution that can be injected into a patient using a syringe filter, characterized in that the syringe filter used has t...  
WO/2022/161967A1
The invention regards a method for 18F-labeling of a peptide.  
WO/2022/157119A1
The invention relates to a PSMA-targeting conjugate or a pharmaceutically acceptable salt which may be used either for preparing a radiopharmaceutical or, once labeled with a radionuclide, as a radiopharmaceutical. The conjugate is of fo...  
WO/2022/135327A1
The present disclosure provides a compound of general formula (I) or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein C is a chelating agent unit, AB is an albumin binding unit, and FAPI is a fibroblast-activa...  
WO/2022/135072A1
Provided in the present invention are a coumarin compound, a preparation method therefor, and the use and a pharmaceutical composition thereof, belonging to the technical field of medicines. The coumarin compound provided in the present ...  
WO/2022/138748A1
The present invention provides a labeling method that comprises a step for labeling a substrate, which has a carbon-hydrogen bond, with an oxygen isotope with use of a catalyst and an oxidant that is produced from a hypervalent iodine co...  
WO/2022/134613A1
The present application relates to the technical field of organic electroluminescence, and provides a nitrogen-containing compound, an electronic component comprising same, and an electronic apparatus. In the compound of the present appl...  
WO/2022/132924A1
The present invention provides novel compounds: (I), and (II) methods of making such compounds, methods of using such compounds for pretargeted imaging, and preparations of formulations for such use.  
WO/2022/123462A1
The present disclosure is related to a compound of Formula 1 Wherein R is H or an effector domain which optionally comprises a linker.  
WO/2022/114333A1
Disclosed is a method for producing of 2-[18F]fluoro-4-boronophenylalanine comprising radioisotopes ([18F]FBPA), the method having a precursor with an effective leaving group and reaction conditions for high-yield synthesis of [18F]FBPA ...  
WO/2022/106714A1
The present invention relates to the radiolabelled compound of enantiomer (R, R) of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphth alen-2-ol, as well as said compound for use in a method for in-vivo diagnosis of, in particu...  
WO/2022/098584A1
A method of purifying radiochemical species (e.g., radiopharmaceuticals) using thin layer chromatography (TLC) plates includes loading one or more TLC plates with a sample containing the radiochemical species to be purified. The one or m...  
WO/2022/098847A1
Disclosed herein are compounds related to tolcapone and its metabolite, 3-OMT, along with 3-deoxytolcapone, as well as pharmaceutical compositions comprising the same. Also disclosed are methods of using such compounds and compositions, ...  
WO/2022/098743A1
The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The appl...  
WO/2022/088853A1
The present invention relates to an organometallic compound and an application thereof. The organometallic compound has a structure represented by formula (1). The compound provided by the present invention has the advantages of high opt...  
WO/2022/090409A1
The invention relates to novel deuterated compounds of Formula (I) to a process for their preparation and to their use as medicament, in particular as antiviral medicament.  
WO/2022/094609A1
Described herein are compounds that are useful for delivering therapeutic, diagnostic, and imaging agents. Also described herein are pharmaceutical compositions containing such compounds and methods of using the compounds and composition...  
WO/2022/071449A1
This deuterated aromatic compound production method for producing a deuterated aromatic compound comprises a step for deuterating an aromatic compound in a deuterium-containing solvent, wherein: the aromatic compound has a structure in w...  
WO/2022/063016A1
The present invention relates to a deuterated dihydrodibenzothiepine compound, a tautomer, stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition containing the compound, and a ...  
WO/2022/058192A1
Phosphatidylalkanol homologues having isotopically labelled moieties, methods for preparation of isotopically labelled phosphatidylalkanol homologues and uses of isotopically labelled phosphatidylalkanol homologues.  
WO/2022/053459A1
The current invention provides a method for performing chemical reactions of radioactive compounds, and a device, system and method for improved heating for chemical reactions.  
WO/2022/045837A1
The present specification relates to a method for preparing a deuterated aromatic compound and a deuterated composition.  
WO/2022/045825A1
The present specification relates to a method for preparing a deuterated aromatic compound and a deuterated composition.  
WO/2022/045838A1
The present specification relates to a method for preparing a deuterated aromatic compound, and a deuterated reactive composition.  
WO/2022/043993A1
The present invention provides PCNHCP pincer metal complexes, which are useful as catalysts in various chemical reactions such as hydrogen isotope exchange (HIE) in C(sp3)-H and/or C(sp2)-H bond of an organic compound, e.g., a pharmaceut...  
WO/2022/038572A1
The present disclosure relates to [18F]-labeled imidazopyridine derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use i...  
WO/2022/034544A1
This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety r...  
WO/2022/034143A1
The present invention relates to an adduct comprising at least one transition metal and an adduct between a sp2 carbon allotrope and a pyrrole compound. In particular, the invention relates to an adduct comprising at least one transition...  
WO/2022/028557A1
A 18F-labeled biphenyl compound, an intermediate thereof, a preparation method therefor, a pharmaceutical composition thereof, and application thereof. The biphenyl compound has a significant suppression effect on PD-1 and/or PD-L1, can ...  
WO/2022/031946A1
Provided herein are compounds of Formula I and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.  
WO/2022/026533A1
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in ...  
WO/2022/019336A1
The purpose of the present invention is to provide: a novel deuterated labeling compound; and a production method therefor. The present invention provides: a deuterated labeling compound in which at least position β of a fatty acid is d...  
WO/2022/016690A1
Provided are luciferase substrates, a preparation method therefor and an application thereof. The luciferase substrates have the advantages of good selectivity, high sensitivity, a low detection line and good biocompatibility, and so on;...  
WO/2022/018264A1
Provided is a ligand compound, comprising (a) a targeting group, (b) one or more chelating groups, optionally containing a chelated radioactive or non-radioactive cation, and (c) a group carrying an Si-OH functional moiety. The ligand co...  
WO/2022/008006A1
The invention relates to compounds of the general formula (I) wherein X1 is a CD2 group or a CT2 group; X2 is oxygen or a group (CZ1Z2)n, with Z1 and Z2 independently of each other being hydrogen, deuterium or tritium and n being an inte...  
WO/2022/003426A1
Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.  
WO/2021/259869A1
The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formula...  
WO/2021/250240A1
The invention relates to a diaza-18-crown-6 derivative having formula (I): wherein: B is a moiety for a covalent bonding reaction; the two A are identical to each other and are a group of formula (II): where: n = 0 to 4; X1, X2, X3, X4 a...  
WO/2021/226076A1
This invention provides a composition comprising the compound having the structure: ethyl 2-[19F]F-4-nitrobenzoate, and at least one acceptable carrier. This invention also provides a method of detecting the presence of or location of ba...  
WO/2021/225147A1
For the purpose of producing astatine-211 free from chloride ions with high yield, an astatine-211 production method is provided, the method being characterized by comprising: (1) a step for irradiating bismuth with an α ray to produce ...  
WO/2021/218588A1
The present application belongs to the field of organic light-emitting materials, and specifically relates to a nitrogen-containing compound, an electronic component using same and an electronic device. The nitrogen-containing compound h...  
WO/2021/219719A1
The present disclosure relates to methods for radiolabelling PSMA binding ligands with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu, and their kits.  
WO/2021/219720A1
The present invention relates to methods for labeling a PSMA binding ligand with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu, said method comprising the steps of: i. providing a single vial comprising, in dried form, said PSMA b...  
WO/2021/222153A1
There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by ac...  
WO/2021/195403A1
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  

Matches 1 - 50 out of 1,633